Symbol | Exchange | Currency |
|---|
When Boohoo Group PLC (LON:BOO) sashays down the City catwalk on Tuesday investors and analysts will be looking the online fast-fashion outfit's first-quarter numbers up and down...
The coming week will see results and updates from a number of major firms including supermarket giant Tesco, online fashion titan Boohoo and Premier Inn owner Whitbread. Meanwhile,...
Time Out Group PLC (LON:TMO) slumped 19% to 37.5p after it revealed it is reviewing an equity funding proposal that would keep it afloat. The company said it has informed London &...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 805.50 | 816.50 | 789.50 | -3.00 | -0.37% | 582.31K | London | |||
| 48.96 | 49.30 | 48.60 | -0.04 | -0.08% | 135.92M | London | |||
| 2,599.50 | 2,614.50 | 2,580.00 | +5.5 | +0.21% | 3.39M | London | |||
| 5,026.00 | 5,030.00 | 4,952.00 | +40.0 | +0.80% | 346.11K | London | |||
| 657.60 | 662.60 | 652.60 | -3.80 | -0.57% | 1.18M | London | |||
| 966.20 | 969.00 | 954.00 | +13.00 | +1.36% | 2.80M | London | |||
| 33.27 | 33.43 | 32.42 | +0.66 | +2.02% | 6.11M | London | |||
| 286.00 | 286.00 | 286.00 | -0.40 | -0.14% | 0.00 | London | |||
| 701.20 | 711.60 | 699.60 | -6.40 | -0.90% | 1.03M | London | |||
| 823.50 | 833.00 | 823.50 | -7.50 | -0.90% | 625.38K | London | |||
| 112.02 | 112.98 | 111.86 | -0.54 | -0.48% | 33.34M | London | |||
| 125.30 | 126.20 | 124.10 | 0.00 | 0.00% | 1.49M | London | |||
| 185.10 | 186.55 | 183.40 | -0.80 | -0.43% | 3.30M | London | |||
| 142.00 | 144.30 | 140.30 | -1.25 | -0.87% | 26.91M | London | |||
| 467.00 | 479.00 | 467.00 | -8.00 | -1.68% | 24.69K | London |
Oxford BioDynamics plc is a United Kingdom-based biotechnology company. The Company is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. It has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.